Olanzapine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Olanzapine
- Olanzapine: From Schizophrenia and Bipolar Disorder to Benign Paroxysmal Torticollis of Infancy
Olanzapine: From Schizophrenia and Bipolar Disorder to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Olanzapine is an atypical antipsychotic originally used for schizophrenia, bipolar disorder and depressive and anxiety disorders. The TxGNN model's top-ranked prediction is benign paroxysmal torticollis of infancy, but no clinical trials and no publications support it. The better-supported candidates are mood and anxiety disorders: neurotic depression and melancholia (systematic reviews and meta-analyses), and agoraphobia (open-label and case-level data).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder (the registration records in Singapore list no indication text) |
| Predicted New Indication | Benign paroxysmal torticollis of infancy |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 19 |
| Recommended Decision | Hold |
The table reflects the top-ranked prediction. Other predictions in the top 10 have stronger evidence and are summarised below.
Other Predicted Indications
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 2 | Agoraphobia | 99.47% | L3 | Research Question |
| 3 | Dysthymic disorder | 99.28% | L4 | Research Question |
| 4 | Distal 17p13.3 microdeletion syndrome | 98.97% | L5 | Hold |
| 5 | Neurotic disorder | 98.93% | L4 | Hold |
| 6 | Neurotic depression | 98.77% | L2 | Research Question |
| 7 | Melancholia | 98.77% | L2 | Research Question |
| 8 | Retinal dystrophy with or without extraocular anomalies | 98.74% | L4 | Hold |
| 9 | Ohdo syndrome and variants | 98.63% | L5 | Hold |
| 10 | Childhood apraxia of speech | 98.63% | L5 | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Olanzapine is known as an atypical antipsychotic that blocks dopamine and serotonin (5-HT2A/5-HT2C) receptors. Its efficacy in psychotic and mood disorders is established.
Top-ranked prediction (benign paroxysmal torticollis of infancy). This is a self-limiting childhood disorder related to the migraine spectrum and often linked to CACNA1A. Any link to olanzapine's receptor pharmacology is speculative. Giving an antipsychotic to infants for a condition that resolves on its own would also raise substantial safety concerns. The high score is a computational prediction only.
Mood and anxiety predictions. Neurotic depression, melancholia and dysthymic disorder overlap with major depression, where olanzapine (especially with fluoxetine) is used as augmentation in treatment-resistant cases. The evidence concerns major depression in general, not these specific labels, and much of the value is already covered by existing indications. For agoraphobia, olanzapine's serotonergic and dopaminergic antagonism may plausibly reduce panic and phobic anxiety, but the data come from panic disorder studies and are indirect.
Genetic and developmental predictions. For distal 17p13.3 microdeletion syndrome, Ohdo syndrome, and childhood apraxia of speech, no credible mechanistic rationale was found. For retinal dystrophy, the only retrieved item is a case report on managing mania in a patient with Usher syndrome. It does not show any effect on the retinal disease.
Clinical Trial Evidence
Currently no related clinical trials are registered for any of the top 10 predicted indications.
Literature Evidence
No literature was found for the top-ranked prediction (benign paroxysmal torticollis of infancy). The most relevant publications for the better-supported predictions are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34986373 | 2022 | Systematic review / NMA | J Affect Disord | Compares augmentation agents in treatment-resistant major depression (neurotic depression, melancholia) |
| 34238049 | 2021 | Systematic review / Meta-analysis | J Psychopharmacol | Antidepressant plus second-generation antipsychotic combinations vs. esketamine vs. lithium in major depression |
| 35861202 | 2023 | Systematic review / Meta-analysis | J Psychopharmacol | Augmentation and combination treatments for early-stage treatment-resistant depression |
| 38360024 | 2024 | Systematic review / NMA | Lancet Psychiatry | Efficacy and safety of drug treatments for psychotic depression |
| 37149344 | 2023 | Review | Psychiatr Clin North Am | Antidepressants and atypical antipsychotics in treatment-resistant depression |
| 36855876 | 2023 | Review | Am J Psychiatry | Role of antipsychotics in the treatment-resistant depression landscape |
| 25963405 | 2016 | Review | Asia Pac Psychiatry | Olanzapine is among three second-generation antipsychotics approved as adjunctive treatment for major depression, effective at subantipsychotic doses |
| 16415705 | 2006 | Open-label trial | J Clin Psychopharmacol | 12-week trial of olanzapine 5 mg/day added to an SSRI in 31 patients with SSRI-resistant panic disorder, with or without agoraphobia |
| 21154393 | 2010 | Review (Cochrane) | Cochrane Database Syst Rev | Second-generation antipsychotics for major depression and dysthymia (indirect for dysthymia) |
| 26635099 | 2016 | Systematic review | Expert Opin Pharmacother | Treatment-resistant panic disorder; antipsychotic augmentation mentioned as a low-evidence option |
| 15470803 | 2004 | Case report | Pharmacopsychiatry | Remission of panic disorder after olanzapine plus paroxetine |
| 10739446 | 2000 | Case report | Am J Psychiatry | Olanzapine and panic attacks |
| 32742822 | 2020 | Case report | Cureus | Olanzapine adjunct for refractory psychogenic excoriation with comorbid schizophrenia |
| 10578457 | 1999 | Clinical study | Biol Psychiatry | Open-label olanzapine in borderline personality disorder with comorbid dysthymia |
Several retrieved items are off-target (rapid-cycling bipolar disorder, valproate, bipolar depression definitions, prescribing-pattern surveys). They are not counted as supporting evidence.
Singapore Market Information
Olanzapine has 19 valid single-ingredient registrations, with no cancelled ones. The registration records provide no approved indication text. Five main authorizations are listed.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09410P | ZYPREXA TABLET 10 mg | Film-coated tablet | Not stated in the registration record |
| SIN09411P | ZYPREXA TABLET 5 mg | Film-coated tablet | Not stated in the registration record |
| SIN12474P | ZYPREXA ZYDIS ORODISPERSIBLE TABLET 10 mg | Tablet | Not stated in the registration record |
| SIN12475P | ZYPREXA ZYDIS ORODISPERSIBLE TABLET 5 mg | Tablet | Not stated in the registration record |
| SIN14228P | Olanzapine Mevon Film-coated Tablets 10 mg | Film-coated tablet | Not stated in the registration record |
All available forms are oral (film-coated tablets, orally disintegrating tablets and plain tablets).
Safety Considerations
Label warnings and contraindications were not available for this report. Please refer to the package insert for authoritative safety information.
- Contraindication-related conditions (from the knowledge graph, not label text): Conditions flagged include orthostatic hypotension, liver failure and liver disease, epilepsy, diabetes mellitus, hyperglycemia, diabetic ketoacidosis, neutropenia, agranulocytosis, hyperlipidemia and hypertriglyceridemia, obesity, benign prostatic hyperplasia, stroke and cerebrovascular disorders, and myocardial infarction. These signal metabolic, haematological, cardiovascular and hepatic cautions.
- Drug Interactions: 100 interactions were recorded. Major-level interactions include bupropion, morphine and potassium citrate. Moderate-level interactions include antidiabetic drugs (metformin, acarbose, alogliptin, canagliflozin, dapagliflozin, chlorpropamide, albiglutide), anticholinergics (atropine, hyoscyamine, glycopyrronium), clarithromycin, famotidine, epinephrine, loperamide and lorcaserin.
- Population concerns: Metabolic and sedative adverse effects are a particular concern in anxiety and depression populations. Use in infants or children for self-limiting or developmental conditions would need strong justification.
Conclusion and Next Steps
Decision: Hold (for the top-ranked prediction, benign paroxysmal torticollis of infancy)
Rationale: The top prediction has only a computational score, with no trials or literature and a poor risk-benefit profile for infants. Neurotic depression and melancholia (L2) and agoraphobia (L3) are better candidates and are classified as Research Questions. Their evidence overlaps with indications olanzapine already covers (major depression) or comes from panic disorder rather than agoraphobia.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, which are currently missing and block safety screening
- Detailed mechanism of action data (MOA) from DrugBank
- Approved indication text for the Singapore registrations
- For agoraphobia: controlled trials in agoraphobia or panic disorder, with a metabolic and sedation monitoring plan
- For depression-related predictions: confirmation that the use falls outside existing major depressive disorder indications, and registered trial evidence
- For the genetic and developmental predictions (rank 1, 4, 8, 9, 10): no further work unless a credible mechanistic rationale emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.